We unpack the FDA 510(k) summary for Tyto Insights for Wheeze Detection (with PCCP). Listeners will learn how this over-the-counter AI software analyzes lung sounds, the real performance numbers behind it, and exactly how the FDA's Predetermined Change Control Plan allows algorithms to be retrained post-clearance without new submissions.
Key points
The software is an over-the-counter AI tool that analyzes 6 to 12-second acoustic lung signals from a compatible stethoscope to detect suspected wheezing in patients 2 years and older.
Performance testing showed a specificity of 0.99 and a sensitivity of 0.55, meaning it rarely flags false positives but misses a significant portion of actual wheezes.
This 510(k) clearance is based on substantial equivalence to a 2023 version of the same product, with the changes being cybersecurity updates and the addition of a Predetermined Change Control Plan (PCCP).
The PCCP allows the company to retrain the machine learning model to improve performance without filing a new 510(k), provided the new version's sensitivity and specificity do not drop below the currently validated thresholds.
The FDA approval letter emphasizes that even with a PCCP, all software modifications must still follow strict Quality Management System Regulations, including design controls and documentation in the Medical Device File.
This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.
Podden och tillhörande omslagsbild på den här sidan tillhör
Mike Rawson. Innehållet i podden är skapat av Mike Rawson och inte av,
eller tillsammans med, Poddtoppen.
